NCT05740618 - Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 28, 2023

Primary Completion Date

January 29, 2025

Study Completion Date

January 29, 2025

Conditions

Cystic Fibrosis

Interventions

DRUG

Mannitol Inhalant Product

A sugar alcohol indicated as an add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis.

Trial Locations (1)

27599

University of North Carolina at Chapel Hill, Chapel Hill